Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: A prognostic score from individual data of nine randomised trials

European Journal of Cancer

Volumn 46, Issue 4, 2010, Pages 735-743

  Di Maio, Massimo ^a   Lama, Nicola ^b   Morabito, Alessandro ^a   Smit, Egbert F ^c   Georgoulias, Vassilis ^d   Takeda, Koji ^e   Quoix, Elisabeth ^f   Hatzidaki, Dora ^d   Wachters, Floris M ^g   Gebbia, Vittorio ^h   Tsai, Chun Ming ⁱ   Camps, Carlos ^j   Schuette, Wolfgang ^k   Chiodini, Paolo ^b   Piccirillo, Maria Carmela ^a   Perrone, Francesco ^a   Gallo, Ciro ^b   Gridelli, Cesare ^l  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^e OSAKA CITY GENERAL HOSPITAL   (Japan)

^f HÔPITAL CIVIL   (France)

^g UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^h UNIVERSITY OF PALERMO   (Italy)

ⁱ TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^j HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^k City Hospital Martha Maria Halle Doelau   (Germany)

^l S G MOSCATI HOSPITAL   (Italy)

more..

Author keywords

Non small cell lung cancer; Pooled analysis; Prognostic factors; Prognostic score; Second line treatment

Indexed keywords

CAPECITABINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; IRINOTECAN; NAVELBINE; PEMETREXED;

ADVANCED CANCER; ARTICLE; CANCER STAGING; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIAGNOSTIC VALUE; HISTOPATHOLOGY; HUMAN; KAPLAN MEIER METHOD; LIFE EXPECTANCY; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEX DIFFERENCE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 76249105307     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.12.013     Document Type: Article

References (30)

1. Gridelli C., Ardizzoni A., Ciardiello F., et al. Second-line treatment of advanced non-small cell lung cancer. J Thorac Oncol 3 (2008) 430-440
2. Murillo J.R., and Koeller J. Chemotherapy given near the end of life by community oncologists for advanced non-small-cell lung cancer. Oncologist 11 (2006) 1095-1099
3. Stinchcombe T.E., and Socinski M.A. Considerations for second-line therapy of non-small cell lung cancer. Oncologist 13 Suppl 1 (2008) 28-36
4. Di Maio M., Perrone F., Chiodini P., et al. Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 25 (2007) 1377-1382
5. Di Maio M., Chiodini P., Georgoulias V., et al. Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 27 (2009) 1836-1843
6. Gridelli C., Gallo C., Di Maio M., et al. A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. Br J Cancer 91 (2004) 1996-2004
7. Gervais R., Ducolone A., Breton J.L., et al. Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol 16 (2005) 90-96
8. Schuette W., Nagel S., Blankenburg T., et al. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol 23 (2005) 8389-8395
9. Lai C.L., Tsai C.M., Chiu C.H., et al. Phase II randomized trial of tri-weekly versus day 1 and 8 weekly docetaxel as a second-line treatment of advanced non-small cell lung cancer. Jpn J Clin Oncol 35 (2005) 700-706
10. Camps C., Massuti B., Jimenez A., et al. Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. Ann Oncol 17 (2006) 467-472
11. Georgoulias V., Kouroussis C., Agelidou A., et al. Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study. Br J Cancer 91 (2004) 482-488
12. Georgoulias V., Agelidou A., Syrigos K., et al. Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study. Br J Cancer 93 (2005) 763-769
13. Wachters F.M., Groen H.J., Biesma B., et al. A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first-line treatment. Br J Cancer 92 (2005) 15-20
14. Gebbia V., Gridelli C., Verusio C., et al. Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients. The DISTAL-2 randomized trial. Lung cancer 63 (2009) 251-258
15. Takeda K., Negoro S., Tamura T., et al. Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104). Ann Oncol 20 (2009) 835-841
16. Smit E.F., Burgers S.A., Biesma B., et al. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J Clin Oncol 27 (2009) 2038-2045
17. Pencina M.J., and D'Agostino R.B. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med 23 (2004) 2109-2123
18. Fibrinogen Studies Collaboration. Measures to assess the prognostic ability of the stratified Cox proportional hazards model. Stat Med 28 (2009) 389-411
19. Royston P., Parmar M.K., and Sylvester R. Construction and validation of a prognostic model across several studies, with an application in superficial bladder cancer. Stat Med 23 (2004) 907-926
20. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., et al. Erlotinib in previously treated non-small cell lung cancer. New Engl J Med 353 (2005) 123-132
21. Kim E.S., Hirsh V., Mok T., et al. Gefitinib versus docetaxel in previously treated (INTEREST): a randomized phase III trial. Lancet 372 (2008) 1809-1818
22. Scagliotti G., Hanna N., Fossella F., et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 14 (2009) 253-263
23. Ciuleanu T., Brodowicz T., Zielinski C., et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 374 (2009) 1432-1440
24. Pirker R., Rodrigues-Pereira J., Szczesna A., et al. Prognostic factors in advanced NSCLC: experience from the FLEX trial. J Clin Oncol 27 (2009) 15s [suppl; abstr 8083]
25. Radzikowska E., Głaz P., and Roszkowski K. Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20 561 cases. Ann Oncol 13 (2002) 1087-1093
26. Fu J.B., Kau T.Y., Severson R.K., and Kalemkerian G.P. Lung cancer in women: analysis of the national Surveillance, Epidemiology, and End Results database. Chest 127 (2005) 768-777
27. Bonomi P., Langer C., O'Brien M., et al. Analysis of prognostic factors in patients with advanced relapsed/refractory NSCLC: Cox regression analysis of a randomized phase III trial comparing docetaxel and paclitaxel poliglumex (PPX). J Clin Oncol 24 18 suppl (2006) 374s
28. Weiss G.J., Rosell R., Fossella F., et al. The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer. Ann Oncol 18 (2007) 453-460
29. Florescu M., Hasan B., Seymour L., Ding K., Shepherd F.A., and National Cancer Institute of Canada Clinical Trials Group. A clinical prognostic index for patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21. J Thorac Oncol 3 (2008) 590-598
30. Clark G.M. Prognostic factors versus predictive factors: examples from a clinical trial of erlotinib. Mol Oncol 1 (2008) 406-412